HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?

Key Takeaways EXAS is benefiting from Cologuard momentum, new test launches and improving EPS projections.HOLX's Molecular unit is expanding with 20+ approved assays and 3,300+ Panther systems installed globally.While HOLX faces tariff pressure, EXAS avoids it due to U.S.-based manufacturing and lab operations.Amid the rising prevalence of cancer worldwide, significant strides have been made in the cancer diagnostics market to improve treatment outcomes and survival rates. According to Roots Analysis, the m ...